Pharmacological inhibition frequently targets both P-gp and ABCG2 (BCRP) at once, sensitizing breast cancer to doxorubicin, and endothelial ovarian cancer cells to paclitaxel and cisplatin [42, 125]. Here, PGP is linked to breast cancer.